Akouos

52 articles with Akouos

• Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting

  5/19/2022

  Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting.

• Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights

  5/12/2022

  Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the first quarter ended March 31, 2022 and provides business highlights.

• Akouos to Present at Bank of America 2022 Healthcare Conference

  5/4/2022

  Akouos, Inc. announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Bank of America 2022 Healthcare Conference on Tuesday, May 10 at 10:00 a.m. PDT in Las Vegas, Nevada.

• Akouos to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting

  5/3/2022

  Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.

• Akouos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

  3/29/2022

  Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the fourth quarter and full year ended December 31, 2021 and provides business highlights.

• Akouos to Participate in Upcoming March 2022 Virtual Investor Conferences

  3/24/2022

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer will participate in two upcoming virtual investor conferences in March.

• 

  BioSpace Movers & Shakers, March 11

  3/11/2022

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers

• Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer

  3/10/2022

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced the appointment of Aaron Tward, M.D., Ph.D., as chief scientific officer.

• Akouos to Present at Cowen 42nd Annual Heath Care Conference

  3/1/2022

  Akouos, Inc. announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a panel discussion titled Auditory and Ophthalmology at the Cowen 42nd Annual Health Care Conference on Monday, March 7 at 2:10 p.m. EST.

• Akouos Presents Nonclinical Data Demonstrating Potential Applicability of Precision Genetic Medicine Platform for a Broad Range of Inner Ear Conditions

  2/7/2022

  Akouos, Inc. presented nonclinical data at the Association for Research in Otolaryngology (ARO) 45th Annual Mid-Winter Meeting that support future development of gene therapies targeting inner ear conditions.

• Akouos to Participate in Upcoming February 2022 Virtual Investor Conferences

  1/31/2022

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that members of the management team will participate in two upcoming virtual investor conferences in February:

• Akouos to Present at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting

  1/7/2022

  Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the Association for Research in Otolaryngology (ARO) 45th Annual Mid-Winter Meeting, which is being held in San Jose, California from February 5 to 9, 2022.

• Akouos to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/22/2021

  Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, participated in a pre-recorded fireside chat that will be published today as part of the Piper Sandler 33rd Annual Healthcare Conference.

• Akouos Reports Third Quarter 2021 Financial Results and Provides Business Highlights

  11/12/2021

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, reports financial results for the third quarter ended September 30, 2021, and provides business highlights.

• 

  BioSpace Movers & Shakers, Nov. 5

  11/5/2021

  Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.

• Akouos Appoints Stacy Price as Chief Technical Officer

  11/1/2021

  Akouos, Inc. today announced the appointment of Stacy Price as chief technical officer.

• Akouos to Present at Jefferies Gene Therapy/Editing Summit

  10/20/2021

  Akouos, Inc. today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27 at 9:30 a.m. EDT.

• Akouos to Present at Upcoming September 2021 Virtual Investor Conferences

  9/7/2021

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will present at two upcoming virtual investor conferences in September

• Akouos Reports Second Quarter 2021 Financial Results and Provides Business Highlights

  8/12/2021

  Akouos, Inc. today reports financial results for the second quarter ended June 30, 2021 and provides business highlights.

• Akouos Announces European Commission Designation of AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss as an Orphan Drug

  8/11/2021

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion on the company’s application for orphan drug designation for AK-OTOF, a gene therapy intended for the treatment of otoferlin gene-mediated hearing loss.